Drug Safety and Availability
Information for consumers and health professionals on new drug warnings and other safety information, drug label changes, and shortages of medically necessary drug products.
Download the Drug Shortages Mobile Application
Drug Safety Communications
- FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks
- La FDA recomienda separar las dosis de sulfonato de poliestireno sódico (Kayexalate) para reducir los niveles de potasio, de las de todo otro medicamento oral
- FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue
Drug Recalls
- Hospira Issues Voluntary Worldwide Recall For Lots of Hydromorphone HCl Injection, USP, CII, (2 mg/mL) 1mg/mL Vial, and Levophed® (Norepinephrine Bitartrate Injection, USP), 4 mg/4 mL (1 mg/mL) Vial, Due to a Lack of Sterility Assurance
- Genentech Issues Voluntary Nationwide Recall of Three Lots of Activase® (Alteplase)-100 mg Due to Lack of Sterility Assurance of the Sterile Water for Injection
- PharMEDium Services, LLC Issues Voluntary Nationwide Recall of all unexpired lots of Oxytocin Compounded with Either Lactated Ringers or Lactated Ringers and Dextrose Due to Sub-Potency
Drug Safety Labeling Changes
Compounding Risk Alerts
Drug Shortages
Subscribe
Sign up to receive emails about Recalls
